Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  cediranib maleate
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-8 of 8 for your search:
Start Over
Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Treatment
Status: Approved-not yet active
Age: Not specified
Sponsor: NCI
Protocol IDs: NCI-2015-00606, NRG-GY004, U10CA180868, NCT02446600
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
Phase: Phase II, Phase I
Type: Tissue collection/Repository, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02015, CDR0000665415, S0905, U10CA032102, SWOG-S0905, NCT01064648
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02938, P8348_A26PAMDREVW01, DFCI IRB 09-293, NCI-2013-00578, NCI-2010-01329, 09-293, 8348, N01CM00071, P30CA006516, U01CA062490, UM1CA186709, NCT01116648
Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 090192, 09-C-0192, NCT00942877
A Trial of Cediranib in the Treatment of Patients With Alveolar Soft Part Sarcoma (CASPS)
Phase: Phase II
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: ICR-CTSU/2010/10027, 2010-021163-33, CRUK/10/021, ISRCTN63733470, ISSRECE0036, NCT01337401
Sunitinib or Cediranib for Alveolar Soft Part Sarcoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 16 to 20
Sponsor: NCI
Protocol IDs: 110200, 11-C-0200, NCT01391962
A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: e-Volve, NCT02340611
Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2015-00051, 9825, P30CA006516, UM1CA186709, NCT02345265
Start Over